Analystreport

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) had its price target lowered by analysts at Citigroup Inc from $12.00 to $10.00.

PhaseBio Pharmaceuticals, Inc.  (PHAS) 
Last phasebio pharmaceuticals, inc. earnings: 3/30 08:01 am Check Earnings Report